FDA approves botulinum toxin A to reduce appearance of wrinkles

07/26/2011 | SkinAndAllergyNews.com

The FDA approved Merz Aesthetics' Xeomin, or incobotulinumtoxinA, for temporarily reducing skin lines and wrinkles. The product is expected to be available in the U.S. next year. Dermatologist and trial investigator Joel Cohen said incobotulinumtoxinA is "more similar than it is different to other products that are on the market, particularly Botox."

View Full Article in:

SkinAndAllergyNews.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Consultant
Attest Health Care Advisors
Nationwide, SL_Nationwide
Biotechnology/Pharmaceutical Patent Attorney
Coats and Bennett PLLC
Cary, NC
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Cargill
Wayzata, MN
Actuary
Meridian Health Plan
Detroit, MI